Project Grant R01AR084627
Award Date
5/15/25
Completion Date
2/28/30
Dollars Obligated
$735K
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $139,895 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to Brigham & Women's Hospital Inc. in Boston, MA. The grant aims to investigate the role of "trained immunity" in linking inflammatory arthritis to the development of cardiovascular disease. Specifically, the research will test the hypothesis that inflammatory responses in...
This federal Project Grant award of $170,101 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research to characterize the spatial heterogeneity of synovial inflammation in rheumatoid arthritis (RA). The principal investigator at Brigham & Women's Hospital Inc. will use advanced statistical techniques and artificial intelligence to identify the spatial...
This federal Project Grant award of $529,616 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research into the role of Notch signaling in driving fibrogenesis and treatment failure in rheumatoid arthritis (RA). The key objectives are to: 1) define the Notch-driven fibrogenic transcriptional program in synovial fibroblasts, 2) determine the impact of this...
This $366,797 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will fund research on the mechanisms of reverse transendothelial migration of neutrophils in the resolution of inflammation. The project, conducted by the University of Missouri System, will investigate how neutrophils that enter infected or damaged tissues can re-enter the bloodstream...
This federal Project Grant award, totaling $495,057 and awarded on July 1, 2024 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), supports research into the biochemical determinants of chemokine receptor signaling. The goal of the project is to biochemically define a new G protein-coupled receptor (GPCR) signaling pathway and investigate its role in T cell signaling, which is relevant to autoimmune skin and connective tissue diseases. The principal...
This Project Grant award, with federal grant ID R01AR084848, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The $664,933 award will support research at Beth Israel Deaconess Medical Center, Inc. to investigate the cellular and molecular mechanisms of interleukin-17A (IL-17A) in the pathogenesis of psoriatic arthritis. The research aims to develop a novel...
The National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University School of Medicine $409,311.92 under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) from April 5, 2021 to January 25, 2022. The project grant funding supports research into the role of T follicular helper (TFH) cells in the pathogenesis of dermatomyositis, a severe inflammatory myopathy. Specifically, the award will fund studies to...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $599,693 to support research into molecular pathways and mechanisms that regulate myeloid cell function and osteoclastogenesis under pathological inflammatory conditions. The research aims to elucidate how inflammation, particularly in the context of orthopedic periprosthetic...
This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
This $529,682 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to investigate the cellular and molecular mechanisms of indoleamine-2,3-dioxygenase (IDO2) function in autoimmune disease. The primary objectives are to define the enzymatic and non-enzymatic pathways through which IDO2 regulates immune responses, with the goal of...